Research Faculty

Address
1130 St. Nicholas Ave.
ICRC 10-04
New York, NY 10032


Phone: 212-851-4624
Fax: 212-851-4660

gs2157@cumc.columbia.edu
Education and Training
1992 B.A. Northwestern University, Evanston, IL
1997 Ph.D. University of Chicago, Chicago, IL


Gloria Su, Ph.D.
Associate Professor of Pathology and Cell Biology (in Otolaryngology—Head & Neck Surgery and in the Herbert Irving Comprehensive Cancer Center) at CUMC
Research Summary

Dr. Gloria Su and her laboratory study the molecular genetics of head and neck squamous cell carcinoma (HNSCC) and pancreatic ductal adenocarcinoma, as well as mouse modeling needed for both cancer types. HNSCC and pancreatic ductal adenocarcinoma are both results of accumulated genetic alterations. Both cancer types share some common oncogenes and tumor-suppressor genes (e.g. p16 and p53), but each has its unique targeted mutations (e.g. Cyclin D1 for HNSCC and K-ras for pancreatic cancer). We continue to compare and contrast the molecular genetic profiles of these two cancer types using both broad genome-scanning approach and candidate-gene approach. By establishing the cancer genetic profiles, we hope to reveal new prognostic markers, discover tumor marker for early detection analysis, and develop chemopreventive and therapeutic treatments that target tumor-specific pathways.

Dr. Su’s laboratory has developed multiple genetically-engineered mouse models that recapitulate human pancreatic cancer at both genetic and histologic levels. Using these genetically-engineered mouse models, Dr. Su’s team is interrogating the biology of tumor development, progression, and metastasis. Notably, her team has reported that the loss of the wild-type KRAS is associated with pancreatic cancer metastasis in mice and in humans. They have also demonstrated that the inactivation of different tumor-suppressor genes following Kras activation may influence the dichotomy of PanIN and IPMN (pancreatic precancerous lesions) development and progression. Specifically, the inactivation of the activin signaling preferentially promotes the development of IPMN. In addition to mouse modeling, Dr. Su and her team have contributed to our understanding of the cancer genetics of human IPMN and recently shown that the dysregulation of the PI3K-PTEN signaling pathway is associated with poor prognosis among IPMN patients.
Selected Publications

W. Qiu, X. Li, H. Tang, A. S. Huang, A. A. Panteleyev, D. M. Owens, G. H. Su. Conditional activin reporter type IB (Acvr1b) knockout mice revealed hair loss abnormality. Journal of Investigative Dermatology 2011, 131:1067-76 (Epub Dec 2010).

A. C. Birkeland, Y. Larrabee, D. T. Kent, C. Flores, G. H. Su, J. H. Lee, J. Haddad. Novel IRF6 mutations in Honduran Van Der Woude syndrome patients. Mol Med Report 2011, 4(2):237-41 (Epub 2011, Jan 11)

Y. C. Larrabee, A. C. Birkeland, D. T. Kent, C. Flores, G. H. Su, J. H. Lee, J. Haddad. Association of common variants, not rare mutations, in IRF6 with non-syndromic clefts in a Honduran population. Laryngoscope 2011, 121:1756-9

J. DiNorcia, M. K. Lee, D. N. Moroziewicz, M. D. Winner, P. Suman, F. Bao, H. E. Remotti, Y. S. Zou, S. F. Yan, W. Qiu, G. H. Su, A. M. Schmidt, J. D. Allendorf. RAGE gene deletion inhibits the development and progression of ductal neoplasia and prolongs survival in a mouse model of pancreatic cancer. Journal of Gastrointestinal Surgery 2012, 16:104-12 (Epub Nov 4, 2011).

W. Qiu, F. Sahin, C.A. Iacobuzio-Donahue, Dario Garcia-Carracedo, W. M. Wang, Chia-Yu Kuo, Dan E. Arking, A. M. Lowy, R. H. Hruban, H. E. Remotti, G. H. Su. Disruption of p16 and Activation of Kras in Pancreas Increases Ductal Adenocarcinoma Formation and Metastasis in vivo. Oncotarget 2011, 2:862-73 (Epub Nov 23, 2011).

C. J. Lennon, A. C. Birkeland, J. A. Pacheco Nunez, G. H. Su, P. Lanzano, E. Guzman, K. Celis, S. B. Eisig, D. Hoffman, M. T. Guerra Rendon, H. Ostos, W. K. Chung, J. Haddad, Jr. Association of candidate genes with nonsyndromic clefts in Honduran and Colombian populations. Laryngoscope 2012, 122:2082-7 (Epub July 2, 2012).

W. Qiu and G. H. Su. Challenges and advances in mouse modeling for human pancreatic tumorigenesis and metastasis. Cancer and Metastasis Review, 2013 June;32(1-2):83-107 (Epub Nov 1, 2012).

W. Qiu and G. H. Su. Development of orthotopic pancreatic tumor mouse models. Methods Mol Biol. 2013; 980:215-23.

D. Gu, H. Liu, G. H. Su, X. Zhang, H. Chin-Sinex, H. Hanenberg, M. Mendonca, H. E. Shannon, E. G. Chiorean, J. Xie. Combining hedgehog signaling inhibition with focal irradiation on reduction of pancreatic cancer metastasis. Molecular Cancer Therapeutics 2013 June; 12(6):1038-48 (Epub March 6, 2013).

R. D. Dinnen, Y. Mao, W. Qiu, N. Cassai, V. N. Slavkovich, G. Nichols, G. H. Su, P. Brandt-Rauf, R. L. Fine. Redirecting apoptosis to aponecrosis induces selective cytotoxicity to pancreatic cancer cells through increased ROS, decline in ATP levels, and VDAC. Molecular Cancer Therapeutics 2013; 12(12):2792-803.

D. Garcia-Carracedo, A. T. Turk, S. A. Fine, N. Akhavan, B. C. Tweel, R. Parsons, J. A. Chabot, J. D. Allendorf, J. M. Genkinger, H. E. Remotti, G. H. Su. Loss of PTEN expression is associated with poor prognosis in patients with intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Research 2013 (Epub Nov 12, 2013).

D. Garcia-Carracedo, Z. Chen, W. Qiu, A. S. Huang, S. M. Tang, R. H. Hruban, G. H. Su. PIK3CA mutations in mucinous cystic neoplasms of the pancreas. Pancreas 2013 (accepted).

W. Qiu, G. Tong, A. T. Turk, L. G. Close, S. M. Caruana, G. H. Su. Oncogenic PIK3CA is overexpressed and mutated in salivary duct carcinoma. BioMed Research International 2013 (acceptable upon revision).

W. Qiu, G. Tong, A. T. Turk, L. G. Close, S. M. Caruana, G. H. Su. Oncogenic PIK3CA is overexpressed and mutated in salivary duct carcinoma. BioMed Research International 2014; 810487. doi: 10.1155/2014/810487. (Epub Jan 8, 2014). PMID: 24511546

D. Garcia-Carracedo, Z. Chen, W. Qiu, A. S. Huang, S. M. Tang, R. H. Hruban, G. H. Su. PIK3CA mutations in mucinous cystic neoplasms of the pancreas. Pancreas, 2014; 43(2):245-9. PMID: 24518503

D. Garcia-Carracedo, C. C. Yu, N. Akhavan, S. A. Fine, F. Schnleben, N. Maehara, D. C. Karg, C. Xie, W. Qiu, R. L. Fine, H. E. Remotti, G. H. Su. Smad4 loss synergizes with TGFalpha overexpression in promoting metaplasia, PanIN development, and fibrosis. PLoS One 2015, Mar 24;10(3):e0120851. PMCID: PMC4372593

J. Peng, P. T. Fullerton Jr., D. Monsivais, C. Clementi, G. H. Su, M. M. Matzuk. Uterine Activin-like Kinase 4 Regulates Trophoblast Development during Mouse Placentation. Molecular Endocrinology 2015; 29(12): 1684-93 (Epub Oct 20, 2015).

W. Qiu, S. M. Tang, S. Lee, A. T. Turk, A. N. Sireci, A. Qiu, C. Rose, C. Xie, J. Kitajewski, H.-J. Wen, H. C. Crawford, P. A. Sims, R. H. Hruban, H. E. Remotti, G. H. Su. Loss of Activin Receptor Type 1B Promotes Development of Intraductal Papillary Mucinous Neoplasms in Mice with Activated KRAS. Gastroenterology 2016; 150 (1)218-228 (Epub Sept 22, 2015).

C. B . Westphalen, Y. Takemoto, T. Tanaka, Macchini M, Z. Jiang, B. W. Renz, X. Chen, S. Ormanns, K. Nagar, Y. Tailor, R. May, Y. Cho, S. Asfaha, D. L. Worthley, Y. Hayakawa, A. M. Urbanska, M. Quante, M. Reichert, J. Broyde, P. S. Subramaniam, H. Remotti, G. H. Su, A. K. Rustgi, R. A. Friedman, B. Honig, A. Califano, C. W. Houchen, K. P. Olive, T. C. Wang. Dclk1 Defines Quiescent Pancreatic Progenitors that Promote Injury-Induced Regeneration and Tumorigenesis. Cell Stem Cell 2016; 18(4):441-55.

D. Garcia-Carracedo, M. ngeles Villaronga, S. lvarez-Teijeiro, F. Hermida-Prado, I. Santamaria, E. Allonca, L. Surez-Fernandez, M. Victoria Gonzalez, M. Balbn, A. Astudillo, P. Martinez-Camblor, G. H. Su, J. Pablo Rodrigo, J. Maria Garcia-Pedrero. Impact of PI3K/AKT/mTOR pathway activation on the prognosis of patients with head and neck squamous cell carcinomas. Oncotarget 2016; 7(20):29780-93.

C. C. Yu, W. Qiu, C. S. Juang, M. M. Mansukhani, B. Halmos, G. H. Su. Mutant allele specific imbalance in oncogenes with copy number alterations: occurrence, mechanisms, and potential clinical implications. Cancer Letters 2016 (Accepted).

Honors and Awards

2015
Distinguished Achievement Award from Shanghai Tongji University East Hospital for exceptional contribution to pancreatic cancer research and clinical management

2014
Ruth Leff Siegel Award for Excellence in Pancreatic Cancer Research

2013-2019
Permanent member, NIH Peer Review Study Section-TPM

2011-present
Grant reviewer, AACR-PanCAN.

2011-2013
Editorial Board, Journal of Otolaryngology (OMICS)

2009
Reviewer, Cancer Council NSW Australia.

2009
External Site Visitor, Site visit for the NCI Cancer Biomarkers Research Group-Early Detection Research Network Laboratories.

2009-2013
Ad Hoc Reviewer, NIH Peer Review Study Section-TPM, TMEN, MONC, Omnibus.

2008-2011
Florence Irving Assistant Professor of Otolaryngology, Irving Institute for Clinical and Translational Research, Columbia University.

2007, 2008, 2009, 2010
Reviewer, Peer Review Study Sections, Department of Defense (DOD)-Congressionally Directed Medical Research Programs (CDMRP)

2006-present
Member, the Executive Board of the Pancreas Center at the Columbia University Medical Center

2003-present
Faculty Member, the Herbert Irving Cancer Research Center at the Columbia University Medical Center

2001-2006
Member, the Editorial Board of the International Journal of Gastrointestinal Cancer, Humana Press.

2002
Co-chair, NIH GI Joint MMHCC-SPORE Meeting, Washington, D.C.

2001-2003
Member, the Research Advisory Council of the Department of Pathology, The Johns Hopkins University
Committees , Council, and Professional Society Memberships

2012-2013
Stem Cell Strategic Plan Committee, Columbia University Medical Center

2000-present
Member of American Association for Cancer Research (AACR)
Keywords

Pancreatic cancer, head and neck cancer, IPMN, mouse modeling, cancer genetics, p16, Kras, activin. PIK3CA.

top
 
 
Contact the Pathology Webmaster at PathWebMaster@columbia.edu